CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
This extension study will evaluate the effectiveness and safety of ocrelizumab in multiple sclerosis (MS) participants who...
Phase 3
Valencia, Spain and 156 other locations
the efficacy and safety of oral masitinib versus placebo in the treatment of patients with primary progressive or secondary progressive multiple...
Phase 3
Valencia, Spain and 36 other locations
To evaluate the safety and efficacy of fingolimod vs. interferon beta-1a i.m. in pediatric patients with multiple sclerosis (MS...
Phase 3
Valencia, Spain and 72 other locations
study will compare ofatumumab vs. European approved platform first line self-administered disease modifying therapy (DMT) in newly diagnosed MS...
Phase 3
Valencia, Spain and 40 other locations
This study aims to examine the efficacy and safety of obexelimab in participants with relapsing multiple sclerosis...
Phase 2
Valencia, Spain and 46 other locations
kinetics of YTB323 in approximately 28 participants with Relapsing Multiple Sclerosis (RMS) with breakthrough disease activity duri...
Phase 1, Phase 2
Valencia, Spain and 15 other locations
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)...
Phase 3
Valencia, Comunidad Valenciana, Spain and 241 other locations
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)...
Phase 3
Valencia, Spain and 249 other locations
of remibrutinib after switching from ocrelizumab and compared to continuous ocrelizumab treatment, in patients living with relapsing multiple...
Phase 3
Valencia, Spain and 27 other locations
This is a Phase 3 extension, global, multicenter study to assess the long-term safety and tolerability of tolebrutinib in adult participants (aged ≥1...
Phase 3
Valencia, Spain and 352 other locations
Clinical trials
Research sites
Resources
Legal